Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts ...

The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its ...

Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the ...

The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.

The approvals stem from the Phase III KEYNOTE-B96 trial data, which was presented at the 2025 ESMO Congress.

By Padmanabhan Ananthan Feb 23 (Reuters) - Merck said on Monday it would create a separate division for its cancer business, anchored by its top-selling drug Keytruda, as the U.S. drugmaker braces for ...

Feb 23 (Reuters) - Drugmaker Merck is separating its human-health business into two divisions to offset pressures related to ...

Dr Parikh explained that KEYNOTE-B15 (NCT04700124) is evaluating the role of perioperative enfortumab vedotin (Padcev), an ...

Adagene (NASDAQ:ADAG) highlighted updated details around its lead immuno-oncology program, ADG126, during an Oppenheimer ...

The new structure will help Merck as it slides toward a loss of exclusivity for Keytruda, pharma’s best-selling drug.

New KEYTRUDA indications are expected to preserve Merck's top line. Click here to read why MRK stock remains a great buy upon ...